Long acting GLP-1 receptor agonist (injectable)
TG103 30 mg injection once weekly
TG103_SC_30MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.68 (0.01 to 51.77) | 0.58 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.69 (0.01 to 53.74) | 0.64 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 13.03 (2.80 to 93.49) | 0.13 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.89 (1.30 to 66.54) | 0.31 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 9.19 (2.13 to 51.23) | 0.08 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 0.71 (0.01 to 47.02) | 0.64 |